Literature DB >> 21248432

Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population.

Saurabh S Rathore1, Surendra K Agarwal, Shantanu Pande, Tulika Mittal, Balraj Mittal.   

Abstract

Dose requirements for oral anticoagulants in thromboembolic events are influenced by polymorphisms in VKORC1 and CYP2C9 genes. The Indian population comprises multiple ethnic groups but no data is available on allele frequencies of these genes for North Indians. The present study aimed at establishing the allele and genotype frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 alleles in the North Indian population. One hundred and two healthy subjects from the Northern Indian region were genotyped for VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 by polymerase chain reaction and restriction fragment length polymorphism. Allele frequencies were compared with that of the HapMap populations. The allele frequencies for VKORC1 -1639 A, CYP2C9*2 and CYP2C9*3 were found to be 14.22%, 4.90% and 3.92% respectively. This report also describes the inter-ethnic differences in the Northern Indian frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 alleles with that of other populations and HapMap project data. VKORC1 -1639 G>A allele is present at moderately high frequency in the Northern Indian population. The frequencies of CYP2C9*2 and CYP2C9*3 alleles are also found to be different from other populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21248432

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  14 in total

1.  The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.

Authors:  Coskun Silan; Omer Tamer Dogan; Fatma Silan; Fatma Mutlu Kukulguven; Halil Fatih Asgun; Semra Ozdemir; Ahmet Uludag; Sinem Atik; Buket Gungor; Seçil Akdur; Hakki Engin Aksulu; Oztürk Ozdemir
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

2.  Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.

Authors:  Saurabh Singh Rathore; Surendra Kumar Agarwal; Shantanu Pande; Sushil Kumar Singh; Tulika Mittal; Balraj Mittal
Journal:  Indian J Clin Biochem       Date:  2011-05-01

3.  Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9.

Authors:  E Khaleqsefat; M Khalaj-Kondori; Bonyadi Jabbarpour; E Battaloğlu
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

Review 4.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

5.  Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.

Authors:  Saurabh Singh Rathore; Surendra Kumar Agarwal; Shantanu Pande; Sushil Kumar Singh; Tulika Mittal; Balraj Mittal
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 6.  Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Chandrasekaran Adithan
Journal:  Indian J Med Res       Date:  2014-01       Impact factor: 2.375

7.  Warfarin pharmacogenetics: How close are we to clinical practice?

Authors:  Tejasvita Gaikwad; Shrimati Shetty; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2013-07

8.  Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.

Authors:  Dhakchinamoorthi Krishna Kumar; Deepak Gopal Shewade; Adithan Surendiran; Chandrasekaran Adithan
Journal:  J Pharmacol Pharmacother       Date:  2013-01

9.  Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement.

Authors:  Anupriya Kaur; Farah Khan; Suraksha S Agrawal; Aditya Kapoor; Surendra K Agarwal; Shubha R Phadke
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

10.  Association of CYP2C9 Genetic Variants with Vitiligo.

Authors:  Abdullateef A Alzolibani; Ahmad Al Robaee; Hani Al-Shobaili; Fahad Al-Saif; Eman Al-Mekhadab; Ahmed A Settin
Journal:  Ann Dermatol       Date:  2014-06-12       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.